ArticleFrontiers in public health2025
Global, regional, and national total burden related to hepatitis B and attributable risk factors in adults aged 65 years and older from 1990 to 2021 and projection to 2030.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Global, regional, and national burden of chronic hepatitis B, 1990-2021, and projections to 2030: An urgent call for action to achieve hepatitis B elimination goals by 2030.Human vaccines & immunotherapeutics · 2026Article
- Trends in Comorbidities and Fatalities Among First-Time Hepatitis B Hospitalizations in Poland (2012-2023).Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- Viral hepatitis detection through emergency hospital departments in a Spanish region with high immigration: implications for elimination strategies.Infectious diseases of poverty · 2026Observational
- New Developments in the Treatment of Hepatitis B Virus Infection.Gastroenterology & hepatology · 2026Article
- IL-6 (-174 G/C) and IL-10 (-1082 G/A) polymorphisms and serum levels in Sudanese patients with end-stage renal disease and overt hepatitis B infection: a pilot comparative study.BMC immunology · 2026Article
- Article
- Hepatitis B in China: the analysis of mortality and burden of disease trends from 2008 to 2021.BMC public health · 2026Article
- Emerging antiviral drugs and immunotherapy for chronic hepatitis B and associated liver disease.Frontiers in immunology · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatitis B virus and its complications remain a major global public health threat. This study aimed to assess the global, regional, and national trends of total burden related to hepatitis B among older adults aged ≥65 years from 1990 to 2021 and predict trend to 2030. Methods: Drawing upon the Global Burden of Diseases (GBD) 2021, we obtained the data on incidence, prevalence, mortality, and disability-adjusted life years (DALYs) from 1990 to 2021, categorized by sex, age, and socio-demographic index (SDI). Associations of. these metrics and SDI were analyzed. Secular trends were evaluated employing average annual percentage changes (AAPC) and joinpoint regression, with future trajectories estimated through 2030 using the Bayesian age-period-cohort (BAPC) model. Results: From 1990 to 2021, the global age-standardized incidence rate (ASIR) of total burden related to hepatitis B among older adults aged ≥65 years declined from 710.53 to 591.79 per 100,000 population (AAPC -0.57%), and age-standardized DALYs rate (ASDR) declined from 927.65 to 605.93 per 100,000 population (AAPC -1.39%). ASIR and ASPR both showed significant decreasing trends in males and females, with persistently higher rates observed among males across all study years. The ASIR increased only in the >95 years age group, while a significant increase in DALYs was observed across all age strata, with the magnitude of increase escalating with advancing age. ASIR increased exclusively in high SDI countries (AAPC 0.16%). In 2021, Central Sub-Saharan Africa accounted for the peak ASIR (1,671.36 per 100,000 population), conversely North Africa and the Middle East showed the most pronounced ASDR decline (AAPC -2.74%). Both alcohol use and smoking emerged as the most consequential modifiable risk factors for DALYs in adults aged ≥65 years. Projections indicate declining trends in ASIR, ASDR, and ASMR for this population by 2030, whereas ASPR is projected to exhibit an upward trend. Conclusion: The global burden and trends of total burden related to hepatitis B among older adults aged ≥65 years showed a significant decline, with projections indicating continued reduction by 2030. However, notable regional and national disparities persist. Key challenges in managing health risks for adults aged ≥65 years remain centered on alcohol use and smoking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.